"This provides further evidence for the use of esketamine nasal ... ketamine. Sun Pharma's Taro unit has made a bid to acquire Canadian biotech Antibe, a developer of drugs for pain and inflammation.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S.

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

SINGAPORE – Ketamine, the controlled drug best known ... first authorized sale of an esketamine nasal spray for serious depression – five psychiatrists who used the therapy on their patients ...

Once seen as an alternative option, the ketamine nasal spray Spravato is now a mainstream prescription for treatment-resistant depression, often recommended in standard guides, he added.

Recreational ketamine use has increased in the United States in recent years, outpacing its rise as a treatment for depression, a new analysis suggests. The hallucinogenic drug — a controlled ...